Ratings Kora Saúde Participações S.A.

Equities

Market Closed - Sao Paulo Other stock markets 04:06:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.7 ^BRL	+1.45%		-.--%	-46.15%

May. 14	Transcript : Kora Saúde Participações S.A., Q1 2024 Earnings Call, May 14, 2024
May. 14	Kora Saúde Participações S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

The company has a low valuation given the cash flows generated by its activity.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

	1st Jan change	Capi.	ESG Refinitiv
KORA SAÚDE PARTICIPAÇÕES S.A.	-46.15%	103M	-
AIER EYE HOSPITAL GROUP CO., LTD.	-23.39%	15.56B	B+
BANGKOK DUSIT MEDICAL SERVICES	-2.70%	11.65B	B
IHH HEALTHCARE	+2.65%	11.58B	B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+2.58%	10.06B	B+
ENCOMPASS HEALTH CORPORATION	+29.48%	8.7B	B
RAMSAY HEALTH CARE LIMITED	-10.66%	7.16B	A-
THE ENSIGN GROUP, INC.	+8.05%	6.85B	B-
MOUWASAT MEDICAL SERVICES COMPANY	+1.07%	6.2B	D
FORTIS HEALTHCARE LIMITED	+9.58%	4.3B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality